Cargando…

Effects of Different Up-Dosing Regimens for Hymenoptera Venom Immunotherapy on Serum CTLA-4 and IL-10

BACKGROUND: Cytotoxic T lymphocyte associated antigen-4 (CTLA-4) is involved in the activation pathways of T lymphocytes. It has been shown that the circulating form of CTLA-4 is elevated in patients with hymenoptera allergy and can be down regulated by immunotherapy. OBJECTIVE: to assess the effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Riccio, Anna Maria, Saverino, Daniele, Pesce, Giampaola, Rogkakou, Anthi, Severino, Maurizio, Bonadonna, Patrizia, Ridolo, Erminia, Mauro, Marina, Canonica, Giorgio Walter, Bagnasco, Marcello, Passalacqua, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3378587/
https://www.ncbi.nlm.nih.gov/pubmed/22723841
http://dx.doi.org/10.1371/journal.pone.0037980
_version_ 1782236063179210752
author Riccio, Anna Maria
Saverino, Daniele
Pesce, Giampaola
Rogkakou, Anthi
Severino, Maurizio
Bonadonna, Patrizia
Ridolo, Erminia
Mauro, Marina
Canonica, Giorgio Walter
Bagnasco, Marcello
Passalacqua, Giovanni
author_facet Riccio, Anna Maria
Saverino, Daniele
Pesce, Giampaola
Rogkakou, Anthi
Severino, Maurizio
Bonadonna, Patrizia
Ridolo, Erminia
Mauro, Marina
Canonica, Giorgio Walter
Bagnasco, Marcello
Passalacqua, Giovanni
author_sort Riccio, Anna Maria
collection PubMed
description BACKGROUND: Cytotoxic T lymphocyte associated antigen-4 (CTLA-4) is involved in the activation pathways of T lymphocytes. It has been shown that the circulating form of CTLA-4 is elevated in patients with hymenoptera allergy and can be down regulated by immunotherapy. OBJECTIVE: to assess the effects on CTLA-4 of venom immunotherapy, given with different induction protocols: conventional (6 weeks), rush (3 days) or ultra rush (1 day). METHODS: Sera from patients with hymenoptera allergy were collected at baseline and at the end of the induction phase. CTLA-4 and IL-10 were assayed in the same samples. A subset of patients were assayed also after 12 months of VIT maintenance. RESULTS: Ninety-four patients were studied. Of them, 50 underwent the conventional induction, 20 the rush and 24 the ultra-rush. Soluble CTLA-4 was detectable in all patients at baseline, and significantly decreased at the end of the induction, irrespective of its duration. Of note, a significant decrease of sCTLA-4 could be seen already at 24 hours. In parallel, IL-10 significantly increased at the end of the induction. At 12 months, sCTLA-4 remained low, whereas IL-10 returned to the baseline values. CONCLUSIONS: Serum CTLA4 is an early marker of the immunological effects of venom immunotherapy, and its changes persist after one year of maintenance treatment.
format Online
Article
Text
id pubmed-3378587
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-33785872012-06-21 Effects of Different Up-Dosing Regimens for Hymenoptera Venom Immunotherapy on Serum CTLA-4 and IL-10 Riccio, Anna Maria Saverino, Daniele Pesce, Giampaola Rogkakou, Anthi Severino, Maurizio Bonadonna, Patrizia Ridolo, Erminia Mauro, Marina Canonica, Giorgio Walter Bagnasco, Marcello Passalacqua, Giovanni PLoS One Research Article BACKGROUND: Cytotoxic T lymphocyte associated antigen-4 (CTLA-4) is involved in the activation pathways of T lymphocytes. It has been shown that the circulating form of CTLA-4 is elevated in patients with hymenoptera allergy and can be down regulated by immunotherapy. OBJECTIVE: to assess the effects on CTLA-4 of venom immunotherapy, given with different induction protocols: conventional (6 weeks), rush (3 days) or ultra rush (1 day). METHODS: Sera from patients with hymenoptera allergy were collected at baseline and at the end of the induction phase. CTLA-4 and IL-10 were assayed in the same samples. A subset of patients were assayed also after 12 months of VIT maintenance. RESULTS: Ninety-four patients were studied. Of them, 50 underwent the conventional induction, 20 the rush and 24 the ultra-rush. Soluble CTLA-4 was detectable in all patients at baseline, and significantly decreased at the end of the induction, irrespective of its duration. Of note, a significant decrease of sCTLA-4 could be seen already at 24 hours. In parallel, IL-10 significantly increased at the end of the induction. At 12 months, sCTLA-4 remained low, whereas IL-10 returned to the baseline values. CONCLUSIONS: Serum CTLA4 is an early marker of the immunological effects of venom immunotherapy, and its changes persist after one year of maintenance treatment. Public Library of Science 2012-06-19 /pmc/articles/PMC3378587/ /pubmed/22723841 http://dx.doi.org/10.1371/journal.pone.0037980 Text en Riccio et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Riccio, Anna Maria
Saverino, Daniele
Pesce, Giampaola
Rogkakou, Anthi
Severino, Maurizio
Bonadonna, Patrizia
Ridolo, Erminia
Mauro, Marina
Canonica, Giorgio Walter
Bagnasco, Marcello
Passalacqua, Giovanni
Effects of Different Up-Dosing Regimens for Hymenoptera Venom Immunotherapy on Serum CTLA-4 and IL-10
title Effects of Different Up-Dosing Regimens for Hymenoptera Venom Immunotherapy on Serum CTLA-4 and IL-10
title_full Effects of Different Up-Dosing Regimens for Hymenoptera Venom Immunotherapy on Serum CTLA-4 and IL-10
title_fullStr Effects of Different Up-Dosing Regimens for Hymenoptera Venom Immunotherapy on Serum CTLA-4 and IL-10
title_full_unstemmed Effects of Different Up-Dosing Regimens for Hymenoptera Venom Immunotherapy on Serum CTLA-4 and IL-10
title_short Effects of Different Up-Dosing Regimens for Hymenoptera Venom Immunotherapy on Serum CTLA-4 and IL-10
title_sort effects of different up-dosing regimens for hymenoptera venom immunotherapy on serum ctla-4 and il-10
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3378587/
https://www.ncbi.nlm.nih.gov/pubmed/22723841
http://dx.doi.org/10.1371/journal.pone.0037980
work_keys_str_mv AT riccioannamaria effectsofdifferentupdosingregimensforhymenopteravenomimmunotherapyonserumctla4andil10
AT saverinodaniele effectsofdifferentupdosingregimensforhymenopteravenomimmunotherapyonserumctla4andil10
AT pescegiampaola effectsofdifferentupdosingregimensforhymenopteravenomimmunotherapyonserumctla4andil10
AT rogkakouanthi effectsofdifferentupdosingregimensforhymenopteravenomimmunotherapyonserumctla4andil10
AT severinomaurizio effectsofdifferentupdosingregimensforhymenopteravenomimmunotherapyonserumctla4andil10
AT bonadonnapatrizia effectsofdifferentupdosingregimensforhymenopteravenomimmunotherapyonserumctla4andil10
AT ridoloerminia effectsofdifferentupdosingregimensforhymenopteravenomimmunotherapyonserumctla4andil10
AT mauromarina effectsofdifferentupdosingregimensforhymenopteravenomimmunotherapyonserumctla4andil10
AT canonicagiorgiowalter effectsofdifferentupdosingregimensforhymenopteravenomimmunotherapyonserumctla4andil10
AT bagnascomarcello effectsofdifferentupdosingregimensforhymenopteravenomimmunotherapyonserumctla4andil10
AT passalacquagiovanni effectsofdifferentupdosingregimensforhymenopteravenomimmunotherapyonserumctla4andil10